TD Cowen analyst Marc Frahm maintained a Buy rating on Revolution Medicines (RVMD – Research Report) today. The company’s shares closed yesterday at $30.88.
Frahm covers the Healthcare sector, focusing on stocks such as Incyte, Agios Pharma, and Revolution Medicines. According to TipRanks, Frahm has an average return of 30.5% and a 50.96% success rate on recommended stocks.
Currently, the analyst consensus on Revolution Medicines is a Strong Buy with an average price target of $37.17, a 20.37% upside from current levels. In a report released on February 28, Stifel Nicolaus also maintained a Buy rating on the stock with a $34.00 price target.
See the top stocks recommended by analysts >>
RVMD market cap is currently $5.09B and has a P/E ratio of -8.18.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Revolution Medicines (RVMD) Company Description:
Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.
Read More on RVMD:
- Revolution Medicines files automatic mixed securities shelf
- Revolution Medicines price target raised to $42 from $41 at Wedbush
- Revolution Medicines sees FY24 GAAP net loss $480M-$520M
- Revolution Medicines reports Q4 EPS ($1.14) , consensus (88c)
- Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress
